98543-10-3

Basic information

• Product Name: 1,2,3,4,6-Penta-O-(3,4,5-Trimethoxybenzoyl)-D-Glucopyranose
• Synonyms: 1,2,3,4,6-Penta-O-(3,4,5-Trimethoxybenzoyl)-D-Glucopyranose
• CAS NO: 98543-10-3
• Molecular Weight: 1151.09
• Mol File: 98543-10-3.mol

Chemical Properties

• CAS DataBase Reference: 1,2,3,4,6-Penta-O-(3,4,5-Trimethoxybenzoyl)-D-Glucopyranose(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4,6-Penta-O-(3,4,5-Trimethoxybenzoyl)-D-Glucopyranose(98543-10-3)
• EPA Substance Registry System: 1,2,3,4,6-Penta-O-(3,4,5-Trimethoxybenzoyl)-D-Glucopyranose(98543-10-3)

Safety Data

• Hazardous Substances Data: 98543-10-3(Hazardous Substances Data)

Upstream product

• 2280-44-6 D-Glucose 
• 118-41-2 Eudesmic acid 

Relevant articles and documents

1,2,3,4,6-Pentakis[-O-(3,4,5-trihydroxybenzoyl)]-α,β-D-glucopyranose (PGG) analogs: Design, synthesis, anti-tumor and anti-oxidant activities

1,2,3,4,6-Pentakis[-O-(3,4,5-trihydroxybenzoyl)]-α,β-D-glucopyranose (PGG) 12 has been reported for its antioxidant activities, where the free OH groups in PGG seem to be critical for activities. To explore PGG-based compounds as chemotherapeutic agents and to analyze the contribution of specific OH groups in PGG for anti-cancer activities, we designed and synthesized a series of 27 benzoic and cinnamic acid analogs of PGG. These analogs were tested for cytotoxicities against two human lung (A549 and H1299) and two human colon (HCT116 and HT29) cancer cell lines. Compound 12 (PGG) had highest cytotoxicities against HCT116 and A549 cells with IC50 of 1.61 μM and 3.02 μM, respectively. In contrast, the compound 16 (1,2,3,4,6-pentakis[-O-(4-hydroxy-3-methoxybenzoyl)]-α,β-D-glucopyranose, PVG) was most effective at killing HT29 and H1299 cells with IC50 of 1.76 μM and 3.65 μM, respectively, indicating the mutual contribution of m-methoxy and p-hydroxy groups to the observed cytotoxicities. Moreover, cinnamic acid analogs were less active than the benzoic acid analogs evidenced by higher IC50 values. Furthermore, in cinnamic acid analogs the hydrogenation of double bond to saturated 2-C side chain enhance the cytotoxicities in all four cell lines. Compounds also possess good anti-oxidant and reducing activities. Compound 12 and 26 show the highest antioxidant and reducing activities.

PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME

The present invention relates to pharmaceutical compositions containing poly(ADP-ribose) glucohydrolase inhibitors, also known as PARG inhibitors, and methods of using the same for inhibiting or decreasing free radical induced cellular energy depletion, cell damage, or cell death. More particularly, the present invention relates to pharmaceutical compositions containing poly (ADP-ribose) glucohydrolase inhibitors such as glucose derivatives; lignin glycosides; hydrolysable tannins including gallotannins and ellagitannins; adenoside derivatives; acridine derivatives including 6,9-diamino-2-ethoxyacridine lactate monohydrate; tilorone analogs including tilorone R10.556, daunomycin or daunorubicin hydrochloride; ellipticine; proflavine; and other PARG inhibitors; and their method of use in treating or preventing diseases or conditions due to free radical induced cellular energy depletion and/or tissue damage resulting from cell damage or death due to necrosis, apoptosis, or combinations thereof.